ClinicalTrials.gg
RecruitingNCT05076682RenaissanceUpdated Oct 23, 2026

Reverse Triple Negative Immune Resistant Breast Cancer

A Phase 2 interventional study of Choline and anti-PD-1 antibody and chemotherapy in Triple-negative Breast Cancer, sponsored by Fudan University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 4 months later.
Updated Oct 23, 2026Enrollment updatedInterventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Triple Negative Breast Neoplasms by Fudan University — 35 open to participants now, 39 under way, 12 of them phase 3. Triple Negative Breast Neoplasms · Fudan University.

Planned enrollment
36th of 62
90 · median 110
Started
2022
with 4 others
Phase 2
41 of 65
20 open now
Primary completion
2026-12
later than 16 of 38 live
Registered
27th of 65
by date

Among the 65 studies in Triple Negative Breast Neoplasms by Fudan University, this one is the 36th largest by planned enrollment of the 62 interventional ones that give a count, is one of 5 that started in 2022, is one of 41 in phase 2, reaches primary completion later than 16 of the 38 other live ones, and was the 27th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

35 of the 65 studies in Triple Negative Breast Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:

29 more — sign in →

By country, each count listing its studies:

All 35 open studies →

Where they have run

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Triple Negative Breast Neoplasms by Fudan University, or all of them as a file.
02

Study summary

This is a Phase II, open-label, nine-arm parallel study evaluating the efficacy and safety of combined treatment (sodium cromoglicate, choline, efavirenz, SHR 1811, SHR 2102, mecapegfilgrastim, theophylline, mifepristone) with immune checkpoint inhibitor or immune checkpoint inhibitor rechallenge(AK131) in mTNBC (triple negative breast cancer) patients who progressed during previous immune checkpoint inhibitors.

Read the detailed description

This is a Phase II, open-label, nine-arm parallel study evaluating the efficacy and safety of combined treatment (sodium cromoglicate, choline, efavirenz, SHR 1811, SHR 2102, mecapegfilgrastim, theophylline, mifepristone) with immune checkpoint inhibitor or immune checkpoint inhibitor rechallenge(AK131) in mTNBC (triple negative breast cancer) patients who progressed during or following previous immune checkpoint inhibitors. The investigators have achieved a breakthrough in the FUTURE study with an ORR (objective response rate) reaching 52.6% in IM (immunomodulatory) subtype TNBC patients. Despite this, there are still some IM subtype patients resistant to immunotherapy. How to reverse immunotherapy resistance or how to increase the sensitivity of immunotherapy efficacy, has become an urgent clinical problem to be solved. The preclinical results of our center show that sodium cromoglicate, choline, efavirenz, SHR 1811, SHR 2102, mecapegfilgrastim, AK131, theophylline, mifepristone play a potentially important role in regulating the tumor immune microenvironment and can inhibit the growth of tumors in mice, and enhance the efficacy of PD-1 inhibitors in mice. Based on preclinical studies, the investigators designed this study to enroll mTNBC patients who have progressed during or following immunotherapy, and to explore the efficacy of these drugs at a clinical level, providing new strategies of combined treatment for TNBC patients.

03

Conditions studied

  • Triple-negative Breast Cancer

Keywords

  • TNBC
  • molecular subtype
  • precision Treatment
  • immunotherapy
  • choline
  • sodium cromoglicate
  • efavirenz
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Performance Status of 0, 1, or 2
  • or locally advanced, documented TNBC (absence of , ER, and PR expression)
  • Radiologic/objective evidence of recurrence or disease progression after immunotherapy(combined with targeted therapy or chemo ) for metastatic breast cancer(MBC)
  • Adequate hematologic and end-organ function, laboratory test results, obtained within 14 days prior to initiation of study treatment.
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use measures as outlined for each specific treatment arm
  • according to v1.1 (RECIST v1.1)
  • have the cognitive ability to understand the protocol and be willing to participate and to be followed up.

Exclusion criteria

Exclusion Criteria:

  • Symptomatic, untreated, or actively progressing
  • Active or history of disease or immune deficiency
  • Significant cardiovascular disease
  • History of other than breast cancer within 5 years prior to screening, with the exception of those with a negligible risk of or death
  • Treatment with chemotherapy, radiotherapy,immunotherapy or surgery (outpatient clinic surgery excluded) within 3 weeks prior to initiation of study treatment.
  • Pregnancy or breastfeeding, or intention of becoming pregnant during the study
  • History of allergies to the drug components of this trial
  • History of eosinophilosis or mastocytosis
  • Patients who have been using oral hormones for a long time will need to stop for 4 weeks if they have used them occasionally in the past
  • For the Mecapegfilgrastim group, patients had previously received PEG-rhG-CSF in combination with immunotherapy.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Choline

    Choline with anti-PD-1 immunotherapy

    Drug: Choline · Drug: anti-PD-1 antibody and chemotherapy

  • Experimental
    Sodium cromoglicate

    Sodium cromoglicate with anti-PD-1 immunotherapy

    Drug: anti-PD-1 antibody and chemotherapy · Drug: Sodium Cromoglicate

  • Experimental
    Efavirenz

    Efavirenz with anti-PD-1 immunotherapy

    Drug: anti-PD-1 antibody and chemotherapy · Drug: Efavirenz

  • Experimental
    HER2 low

    HER2 low expression

    Drug: SHR-A1811 · Drug: SHR-1316

  • Experimental
    HER2 0

    HER2 0 expression

    Drug: SHR-A2102 · Drug: SHR-1316

  • Experimental
    AK131

    AK131(CD73/PD1 bispecific antibody)

    Drug: AK131

  • Experimental
    Mecapegfilgrastim

    Mecapegfilgrastim with anti-PD-1 immunotherapy

    Drug: anti-PD-1 antibody and chemotherapy · Drug: Mecapegfilgrastim

  • Experimental
    Theophylline

    Theophylline with anti-PD-1 immunotherapy

    Drug: Theophylline

  • Experimental
    Mifepristone

    Mifepristone with anti-PD-1 immunotherapy

    Drug: anti-PD-1 antibody and chemotherapy · Drug: Mifepristone

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Time frame: Baseline until disease progression or loss of clinical benefit, assessed up to 6 months

  2. Immune changes in peripheral blood

    Time frame: Baseline until disease progression or loss of clinical benefit, assessed up to 6 months

Secondary outcomes

  1. Disease Control Rate (DCR)

    Time frame: Baseline through end of study, assessed up to 6 months

  2. Progression Free Survival (PFS)

    Time frame: Randomization to death from any cause, through the end of study,assessed up to 6 months

  3. Safety and treatment-related AEs

    Time frame: Randomization to death from any cause, through the end of study,assessed up to 12 months

  4. Biomarker analysis1

    Mast cell function will be measured in pretreatment tissues to predict therapy response.

    Time frame: Baseline until disease progression or loss of clinical benefit, assessed up to 6 months

  5. Biomarker analysis2

    Immunohistochemical staining of pre- and post-treatment tissue sections was carried out to evaluate PD-L1 expression, mast cell function, innate lymphoid cell porprotion and activity, and overall inflammatory status

    Time frame: Baseline until disease progression or loss of clinical benefit, assessed up to 6 months

  6. Biomarker analysis3

    The quantity and function of innate lympoid cells will be measured in tissues and/or peripheral blood before and after treatment

    Time frame: Baseline until disease progression or loss of clinical benefit, assessed up to 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wu SY, Jin X, Liu Y, Wang ZY, Zuo WJ, Ma D, Xiao Y, Fu T, Xiao YL, Chen L, Liu XY, Fan L, Wang ZH, Shen M, Liu R, Chai WJ, Shao ZM, Jiang YZ. Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial. Nat Med. 2025 Jul;31(7):2405-2415. doi: 10.1038/s41591-025-03776-7. Epub 2025 Jun 25. PubMed 40563015 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Dec 2026, 54 months after the start.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 54 months is close to that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2021
First posted
Oct 13, 2021
StartActual
Jun 30, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
80→90
Oct 23, 2026
Interventions
Added Drug: Mifepristone. Arms added: Mifepristone
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Enrollment 80→90
    Interventions Added Drug: Mifepristone. Arms added: Mifepristone
    + 3 other changes: verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05076682
Lead sponsor
Fudan University
Responsible party
Zhimin Shao (Professor, Fudan University) — Principal investigator
First posted
Oct 13, 2021
Start date
Jun 30, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Zhimin Shao, Professor
Contact
zhimingshao@yahoo.com
08664175590 ext. 88807
Zhonghua Wang, Professor
Contact
zhonghuawang95@hotmail.com
08664175590 ext. 88807
Zhimin Shao, Professor
principal investigator · Fudan U

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Choline · Cromolyn · Efavirenz · Adebrelimab · Pegylated granulocyte colony-stimulating factor · Theophylline · Mifepristone

Start the discussion